Segantii Capital Management LTD Cerevel Therapeutics Holdings, Inc. Transaction History
Segantii Capital Management LTD
- $807 Million
- Q1 2024
A detailed history of Segantii Capital Management LTD transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Segantii Capital Management LTD holds 1,143,426 shares of CERE stock, worth $0. This represents 5.99% of its overall portfolio holdings.
Number of Shares
1,143,426
Previous 594,519
92.33%
Holding current value
$0
Previous $25.2 Million
91.74%
% of portfolio
5.99%
Previous 2.46%
Shares
2 transactions
Others Institutions Holding CERE
# of Institutions
270Shares Held
155MCall Options Held
2.19MPut Options Held
3.92M-
Bain Capital Investors LLC Boston, MA65.7MShares$065.37% of portfolio
-
Perceptive Advisors LLC New York, NY10.8MShares$012.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY7.54MShares$04.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.15MShares$00.01% of portfolio
-
Black Rock Inc. New York, NY3.56MShares$00.0% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...